Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

4D Molecular Therapeutics, Inc. - Common Stock (NQ:FDMT)

3.060 +0.150 (+5.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 377,853
Open 2.900
Bid (Size) 3.060 (58)
Ask (Size) 3.070 (38)
Prev. Close 2.910
Today's Range 2.890 - 3.070
52wk Range 2.235 - 28.93
Shares Outstanding 42,052,980
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
4DMT Announces New Employment Inducement Grants
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-47.5%
-47.5%
1 Month
-19.9%
-19.9%
3 Month
-34.6%
-34.6%
6 Month
-63.8%
-63.8%
1 Year
-87.9%
-87.9%

More News

Read More
4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Forecasting The Future: 7 Analyst Projections For 4D Molecular Therapeutics
Via Benzinga
A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 9 Analysts
Via Benzinga
4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study
Via Benzinga
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 6 Analysts
Via Benzinga
4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
What 5 Analyst Ratings Have To Say About 4D Molecular Therapeutics
Via Benzinga
Analyst Expectations For 4D Molecular Therapeutics's Future
Via Benzinga
Amazon To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
The Latest Analyst Ratings For 4D Molecular Therapeutics
Via Benzinga
4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate
Via Benzinga
4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Kaskela Law LLC Announces Stockholder Investigation of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) and Encourages Investors to Contact the Firm
From Kaskela Law LLC
Via Business Wire
FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire

Frequently Asked Questions

Is 4D Molecular Therapeutics, Inc. - Common Stock publicly traded?
Yes, 4D Molecular Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does 4D Molecular Therapeutics, Inc. - Common Stock trade on?
4D Molecular Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for 4D Molecular Therapeutics, Inc. - Common Stock?
The ticker symbol for 4D Molecular Therapeutics, Inc. - Common Stock is FDMT on the Nasdaq Stock Market
What is the current price of 4D Molecular Therapeutics, Inc. - Common Stock?
The current price of 4D Molecular Therapeutics, Inc. - Common Stock is 3.060
When was 4D Molecular Therapeutics, Inc. - Common Stock last traded?
The last trade of 4D Molecular Therapeutics, Inc. - Common Stock was at 04/17/25 04:00 PM ET
What is the market capitalization of 4D Molecular Therapeutics, Inc. - Common Stock?
The market capitalization of 4D Molecular Therapeutics, Inc. - Common Stock is 128.68M
How many shares of 4D Molecular Therapeutics, Inc. - Common Stock are outstanding?
4D Molecular Therapeutics, Inc. - Common Stock has 129M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.